Generic ADHD medications and authorized generics: what "equivalent" means

Most adults on ADHD medication take a generic at some point, sometimes without asking for it. Generics usually cost less, but people sometimes report that a new bottle seems to work differently, and the history of generic Concerta shows the question is not always imaginary. This article explains how the FDA decides that a generic is equivalent, what happened with methylphenidate extended-release tablets, what an authorized generic is, and how substitution works at pharmacies in New York and New Jersey. It does not recommend brand over generic or the reverse.

What the FDA requires of a generic

According to the FDA, a generic drug must be the same as the brand-name drug in active ingredient, conditions of use, dosage form, strength, route of administration and (with certain permitted differences) labeling. The company must show it is bioequivalent, meaning it "gets to the part of the body where the drug works at the same time and in the same amount." Inactive ingredients can differ, so the color, shape and filler of a generic often do.

Reading the Orange Book codes

The FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, known as the Orange Book, gives each approved product a therapeutic equivalence code. The preface explains them:

The numbered codes matter for one ADHD product family. In the October 2026 data, generic mixed amphetamine salts extended-release capsules rated AB1 are equivalent to Adderall XR, while those rated AB2 are equivalent to Mydayis. They contain the same four salts but are not interchangeable with each other. The Orange Book preface also says it does not mandate which products are purchased, prescribed, dispensed or substituted, and that substitution is a matter of state law.

The generic Concerta story

Concerta is an extended-release methylphenidate tablet that its 2023 label described as an osmotic delivery system, releasing drug over many hours. The FDA's public record shows what happened with its first generics:

• November 13, 2014: the FDA announced concerns that two generic versions, made by Mallinckrodt and Kudco, might not be therapeutically equivalent. Its analysis found they "may deliver drug in the body at a slower rate during the 7- to 12-hour range," which could mean patients do not get the desired effect. It changed their rating from AB to BX. The products stayed approved and could still be prescribed, but were no longer recommended for automatic substitution. The FDA asked the companies to confirm bioequivalence within six months or withdraw the products.
• Same notice: the authorized generic, marketed by Actavis under a licensing agreement with the brand company, was found bioequivalent and substitutable.
• October and November 2016: the FDA proposed withdrawing approval of both products, saying the companies had failed to show their products provide the same therapeutic effect. On October 21, 2016 it approved another generic, marketed by Mylan.

The current picture comes from the Orange Book data files dated October 9, 2026. Generic methylphenidate extended-release tablets in Concerta's strengths from seven manufacturers were rated AB, and one product, held by Lannett, remained rated BX. This guide did not confirm whether the 2016 withdrawal proposals were completed or how the BX product relates to the 2014 products. If you want to know the rating of the exact product you received, ask the pharmacist for the manufacturer and check it in the Orange Book.

Product detail is in Concerta for adults and brand vs generic Concerta.

Authorized generics

The FDA describes an authorized generic as an approved brand-name drug marketed without the brand name on its label. It is the exact same drug product, though a tablet or capsule may have a different color or marking. It may be sold by the brand company or by another company with permission. Because it is marketed under the brand's own application, it is not listed separately in the Orange Book, and the FDA considers it therapeutically equivalent to the brand.

The FDA's listing of authorized generics, updated October 5, 2026, includes entries for several ADHD stimulants: Adderall XR, Focalin XR, Ritalin, Ritalin LA, Relexxii, Dexedrine Spansule and Methylin oral solution. Concerta does not appear on the listing, even though the FDA's 2014 notice described the Actavis product as an authorized generic identical to Concerta. The FDA cautions that the listing may be incomplete and does not say whether each product is still marketed.

Which ADHD medications have generics (October 2026)

Having many generic makers does not guarantee supply. As of October 2026 the FDA drug shortage database still listed lisdexamfetamine and methylphenidate extended-release tablets as current shortages. See ADHD medication shortages in New York and in New Jersey.

Substitution at the pharmacy in New York and New Jersey

• New York: Education Law section 6816-a says a pharmacist "shall substitute a less expensive drug product" with the same active ingredients, dosage form and strength when the prescription does not prohibit substitution and the product is on the state's list. The label must show the name, strength and manufacturer of the drug dispensed, unless the prescriber specifies otherwise.
• New Jersey: under the state's generic substitution law (N.J.S.A. 24:6E), the prescriber can indicate that there shall be no substitution, interchangeable products are those the Department of Health has determined to be therapeutic equivalents, and pharmacies must post signs saying whether a drug may be substituted from the state's list of interchangeable products.

In practice, if you or your prescriber want a specific product, the prescription has to say so, and your insurance plan may charge more for the brand. Cost details are in ADHD medication cost in New York and in New Jersey.

Switching generic manufacturers: amphetamine salts and other stimulants

Your prescription can stay the same while the maker changes from one fill to the next. Generic Adderall (mixed amphetamine salts) is a common example, and the same can happen with other generic stimulants.

What the ratings show

The Orange Book data dated October 9, 2026, still the current file when checked on November 4, 2026, list these approved prescription products:

A listing shows approval. It does not show that a product is being sold or is in stock at your pharmacy. The Orange Book lists brand Adderall immediate-release tablets as discontinued, and it names a generic as the reference standard. A 2023 paper by FDA and Harvard-affiliated authors notes that this reference product has been sold under both the Adderall name and the generic name, so a bottle's name does not tell you the whole story. Background on the drug itself is in Adderall and amphetamine salts for adults.

What the FDA says about differences

The FDA says generics are designed to have the same clinical effect and safety profile as the brand, but that small, allowable differences between manufacturers' products, such as certain inactive ingredients, "can sometimes feel noticeable to patients." It says inactive ingredients in most cases do not matter clinically, though in a minority of patients they may affect tolerability or absorption. It describes this as usually minor and uncommon, but worth clinical attention if patients report concerns.

Patient reports: what they do and do not show

Some patients report that a particular generic seems less effective. These are real experiences, but a report alone cannot show that the product caused the change. The paper described below also notes that negative views about generics are likely associated with more side effect reporting and lower adherence.

• Reports to the FDA. Certain generic immediate-release mixed amphetamine salts products were the subject of spontaneous reports to the FDA describing lack of effectiveness, largely among long-term users.
• What the FDA looked at. Researchers from the FDA and Harvard Medical School examined 2013 to 2019 insurance claims for people aged 15 to 64 with ADHD or narcolepsy. Their descriptive analysis did not suggest more switching away from, or back after, the generics of interest. The authors said the data cannot confirm a bioequivalence issue, listed other limits, and called for continued surveillance.
• When the FDA acts. In the generic Concerta history above, the FDA cited an analysis of adverse event reports, a re-examination of data and its own laboratory tests. The FDA says it may change a therapeutic equivalence code if it finds a potential equivalence issue, and that there is no fixed number of reports that triggers action.

This guide's search found no published trial comparing patient outcomes before and after a switch between generic stimulant manufacturers, as of November 2026.

If a new generic seems to work differently

• Check the label for the manufacturer and compare it with your last fill. In New York the label must generally show the manufacturer. New Jersey's labeling rule does not list the manufacturer among its required items, so ask the pharmacist.
• If a pill looks different, ask the pharmacist to check the imprint before you take it. Federal rules require most solid oral drugs to carry a code imprint that, with size, shape and color, identifies the product and its manufacturer or distributor. Labels on DailyMed usually describe each product's appearance under "How Supplied."
• Do not take a pill nobody can identify. A new look can simply mean a new maker, but the FDA lists a different look as one possible sign of a counterfeit, and says to buy only from state-licensed pharmacies.
• Write down what changed and when, such as earlier wearing off, more side effects or less effect.
• Tell your prescriber, and share the manufacturer's name. Do not change how you take the medication on your own.
• Ask the pharmacy whether it can order the maker you had before. It may not be able to, and this is not guaranteed. A prescriber can also discuss whether a specific product should be noted on the prescription.
• You or your clinician can report a suspected problem to the FDA through MedWatch. The FDA says this covers product quality problems and therapeutic inequivalence or failure. You can use the online form, Form FDA 3500B, or 1-888-INFO-FDA (press 2), and its generic drug page also points patients to its SmartHub reporting site. You can report even if you are not sure the drug caused the problem.
• Get medical help right away for a severe reaction. Do not wait to file a report.

Dr. Shershow, a psychiatrist licensed in New York and New Jersey, provides ongoing follow-up for adults on ADHD medication, which is the place to raise a change like this. See adult ADHD treatment.